Immix Biopharma, Inc. (IMMX)
NasdaqCM · Biotechnology
Scores are generated from technical indicators for educational purposes and are not a recommendation to buy or sell.
Price history
Daily closes and volumeAI Analysis Generated from the indicator readings below. Educational only.
Immix Biopharma, Inc. is trading at $7.68, down 3.76% on the session. The 50 day average sits at $11.02 and the 200 day at $9.48, which puts the stock in a uptrend. RSI is at 30.2, which reads as weak, and MACD is bullish crossover. Volume is average.
The nearest support is around $7.56 with resistance near $9.10, so that band frames the current range. Average daily movement is roughly $0.61, or about 7.9% of the share price, which is what any stop placement has to allow for. The overall health score of 41 out of 100 combines a trend score of 33, momentum of 44 and a risk score of 48.
Technical indicators
About Immix Biopharma, Inc.
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Company website